[{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"PAION UK LTD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Acacia Pharma \/ PAION UK LTD","highestDevelopmentStatusID":"9","companyTruncated":"Acacia Pharma \/ PAION UK LTD"},{"orgOrder":0,"company":"PAION UK LTD","sponsor":"University Medical Center Groningen | QPS Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"PAION UK LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PAION UK LTD \/ University Medical Center Groningen | QPS Holdings","highestDevelopmentStatusID":"10","companyTruncated":"PAION UK LTD \/ University Medical Center Groningen | QPS Holdings"},{"orgOrder":0,"company":"Korea University Guro Hospital","sponsor":"Hana Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase IV","graph3":"Korea University Guro Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Korea University Guro Hospital \/ Hana Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Korea University Guro Hospital \/ Hana Pharm"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Daegu Catholic University Medical Center","sponsor":"Hana Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Daegu Catholic University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daegu Catholic University Medical Center \/ Hana Pharm","highestDevelopmentStatusID":"10","companyTruncated":"Daegu Catholic University Medical Center \/ Hana Pharm"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Peking Union Medical College Hospital \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"PAION UK LTD","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nantes University Hospital \/ PAION UK LTD","highestDevelopmentStatusID":"8","companyTruncated":"Nantes University Hospital \/ PAION UK LTD"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Hana Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seoul National University Hospital \/ Hana Pharm","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Hana Pharm"},{"orgOrder":0,"company":"Kangbuk Samsung Hospital","sponsor":"Hana Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kangbuk Samsung Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kangbuk Samsung Hospital \/ Hana Pharm","highestDevelopmentStatusID":"1","companyTruncated":"Kangbuk Samsung Hospital \/ Hana Pharm"}]

Find Clinical Drug Pipeline Developments & Deals for Remimazolam Besylate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 22, 2024

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Wuhan Union Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Wuhan Union Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 01, 2023

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Yichang Humanwell Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Wuhan Union Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Wuhan Union Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 09, 2023

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Yichang Humanwell Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Wuhan Union Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Wuhan Union Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 24, 2023

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase III

                          Sponsor : Yichang Humanwell Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Daegu Catholic University Medical Center

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Daegu Catholic University Medical Center

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          December 02, 2022

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase III

                          Sponsor : Hana Pharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Korea University Guro Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Korea University Guro Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          June 21, 2022

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Hana Pharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Kangbuk Samsung Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Kangbuk Samsung Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          May 02, 2022

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Hana Pharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          September 17, 2021

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Hana Pharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peking Union Medical College Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Peking Union Medical College Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 01, 2021

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Yichang Humanwell Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          April 20, 2021

                          Lead Product(s) : Remimazolam Besylate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : PAION UK LTD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank